Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Page 1
Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study.
Herfarth K, Borchmann P, Schnaidt S, Hohloch K, Budach V, Engelhard M, Viardot A, Engenhart-Cabillic R, Keller U, Reinartz G, Eich HT, Witzens-Harig M, Hess CF, Dörken B, Dürig J, Wiegel T, Hiddemann W, Hoster E, Pott C, Dreyling M. Herfarth K, et al. Among authors: dorken b. Hemasphere. 2018 Nov 30;2(6):e160. doi: 10.1097/HS9.0000000000000160. eCollection 2018 Dec. Hemasphere. 2018. PMID: 31723798 Free PMC article.
For the primary endpoint, PFS at 2 years was 85% for the intention-to-treat set. Long-term data were captured in selected sites and evaluated as post hoc analysis in the per protocol (PP) set: PFS and OS were 78% and 96% at 5 years with a median follow-up of 66 or 78 month …
For the primary endpoint, PFS at 2 years was 85% for the intention-to-treat set. Long-term data were captured in selected sites and e …
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis.
Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, Peest D, Kaufmann M, Bunjes D, Straka C, Fischer T, Sezer O, Hentrich M, Ostermann H, Bassermann F, Hess G, Hertenstein B, Freund M, Kropff M, Schmidt CA, Wolf HH, Jung W, Frickhofen N, Mielke S, Bargou RC, Maschmeyer G, Svaldi M, Langer CH, Gramatzki M, Hebart H, Kanz L, Einsele H; Deutsche Studiengruppe Multiples Myelom. Knop S, et al. Leukemia. 2019 Nov;33(11):2710-2719. doi: 10.1038/s41375-019-0537-2. Epub 2019 Aug 28. Leukemia. 2019. PMID: 31462732 Clinical Trial.
AML: high serum ferritin at initial diagnosis has a negative impact on long-term survival.
Ihlow J, Gross S, Sick A, Schneider T, Flörcken A, Burmeister T, Türkmen S, Arnold R, Dörken B, Westermann J. Ihlow J, et al. Among authors: dorken b. Leuk Lymphoma. 2019 Jan;60(1):69-77. doi: 10.1080/10428194.2018.1461860. Epub 2018 May 30. Leuk Lymphoma. 2019. PMID: 29846127
Increased serum ferritin (SF) is common in hematologic malignancies; however, its prognostic role in acute myeloid leukemia (AML) is not clearly established. We examined the impact of baseline SF on long-term survival in 137 intensively treated AML patients. Patients and b …
Increased serum ferritin (SF) is common in hematologic malignancies; however, its prognostic role in acute myeloid leukemia (AML) is not cle …
Allogeneic stem cell transplantation for non-de novo AML or advanced myelodysplastic syndromes: influence of GvHD and donor lymphocyte infusions on long-term outcome.
Hemmati PG, Pfeifer K, Vuong LG, Jehn CF, Terwey TH, le Coutre P, Dörken B, Arnold R. Hemmati PG, et al. Among authors: dorken b. Bone Marrow Transplant. 2018 Jan;53(1):101-103. doi: 10.1038/bmt.2017.215. Epub 2017 Oct 9. Bone Marrow Transplant. 2018. PMID: 28991253 No abstract available.
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau BM, Grützmann R, Weinmann A, Maschmeyer G, Pelzer U, Stieler JM, Striefler JK, Ghadimi M, Bischoff S, Dörken B, Oettle H, Riess H. Sinn M, et al. Among authors: dorken b. J Clin Oncol. 2017 Oct 10;35(29):3330-3337. doi: 10.1200/JCO.2017.72.6463. Epub 2017 Aug 17. J Clin Oncol. 2017. PMID: 28817370 Clinical Trial.
There was no difference in median DFS (GemErlo 11.4 months; Gem 11.4 months) or median overall survival (GemErlo 24.5 months; Gem 26.5 months). There was a trend toward long-term survival in favor of GemErlo (estimated survival after 1, 2, and 5 years for GemErlo was 77%, …
There was no difference in median DFS (GemErlo 11.4 months; Gem 11.4 months) or median overall survival (GemErlo 24.5 months; Gem 26.5 month …
Long-term follow-up of fertility and pregnancy in autoimmune diseases after autologous haematopoietic stem cell transplantation.
Massenkeil G, Alexander T, Rosen O, Dörken B, Burmester G, Radbruch A, Hiepe F, Arnold R. Massenkeil G, et al. Among authors: dorken b. Rheumatol Int. 2016 Nov;36(11):1563-1568. doi: 10.1007/s00296-016-3531-2. Epub 2016 Aug 13. Rheumatol Int. 2016. PMID: 27522225
Issues of fertility and pregnancy require special attention in the long-term care of patients with autoimmune diseases (AD), who are candidates for haematopoietic stem cell transplantation (HSCT). ...Although AD patients undergoing HSCT are at risk of developing infertilit …
Issues of fertility and pregnancy require special attention in the long-term care of patients with autoimmune diseases (AD), who are …
CD20-Targeting Immunotherapy Promotes Cellular Senescence in B-Cell Lymphoma.
Däbritz JH, Yu Y, Milanovic M, Schönlein M, Rosenfeldt MT, Dörr JR, Kaufmann AM, Dörken B, Schmitt CA. Däbritz JH, et al. Among authors: dorken b. Mol Cancer Ther. 2016 May;15(5):1074-81. doi: 10.1158/1535-7163.MCT-15-0627. Epub 2016 Feb 15. Mol Cancer Ther. 2016. PMID: 26880268
The CD20-targeting monoclonal antibody rituximab is an established component of immunochemotherapeutic regimens against B-cell lymphomas, where its coadministration with conventional anticancer agents has significantly improved long-term outcome. However, the cellular mech …
The CD20-targeting monoclonal antibody rituximab is an established component of immunochemotherapeutic regimens against B-cell lymphomas, wh …
Frequent induction of chromosomal aberrations in in vivo skin fibroblasts after allogeneic stem cell transplantation: hints to chromosomal instability after irradiation.
Massenkeil G, Zschieschang P, Thiel G, Hemmati PG, Budach V, Dörken B, Pross J, Arnold R. Massenkeil G, et al. Among authors: dorken b. Radiat Oncol. 2015 Dec 30;10:266. doi: 10.1186/s13014-015-0576-4. Radiat Oncol. 2015. PMID: 26715553 Free PMC article.
CONCLUSION: High-dose chemotherapy and TBI leads to severe chromosomal damage in skin fibroblasts of patients after SCT. Our long-term data suggest that this damage increases with time, possibly due to in vivo radiation-induced chromosomal instability....
CONCLUSION: High-dose chemotherapy and TBI leads to severe chromosomal damage in skin fibroblasts of patients after SCT. Our long-term …
Apoptosis Susceptibility Prolongs the Lack of Memory B Cells in Acute Leukemic Patients After Allogeneic Hematopoietic Stem Cell Transplantation.
Mensen A, Oh Y, Becker SC, Hemmati PG, Jehn C, Westermann J, Szyska M, Göldner H, Dörken B, Scheibenbogen C, Arnold R, Na IK. Mensen A, et al. Among authors: dorken b. Biol Blood Marrow Transplant. 2015 Nov;21(11):1895-906. doi: 10.1016/j.bbmt.2015.08.008. Epub 2015 Aug 10. Biol Blood Marrow Transplant. 2015. PMID: 26271190 Free article.
Long-term survival after allogeneic hematopoietic stem cell transplantation requires intact immunosurveillance, which is hampered by lymphoid organ damage associated with conditioning therapy, graft-versus-host disease, and immunosuppression. ...Follow-up studies should ev …
Long-term survival after allogeneic hematopoietic stem cell transplantation requires intact immunosurveillance, which is hampered by …
Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome.
Hemmati PG, Terwey TH, Na IK, Jehn CF, le Coutre P, Vuong LG, Dörken B, Arnold R. Hemmati PG, et al. Among authors: dorken b. Eur J Haematol. 2015 Dec;95(6):498-506. doi: 10.1111/ejh.12522. Epub 2015 Mar 24. Eur J Haematol. 2015. PMID: 25598394
For patients with refractory acute myeloid leukemia (AML), allogeneic stem cell transplantation (alloSCT) represents the only curative approach. We here analyzed the long-term outcome of 131 consecutive patients with active AML, which was either primary refractory or unres …
For patients with refractory acute myeloid leukemia (AML), allogeneic stem cell transplantation (alloSCT) represents the only curative appro …
33 results